From ₹51 Cr to ₹1,272 Cr in a year—this Indian biotech’s revenue chart is insane.
💰 Molbio is going public targeting ₹22,000–24,000 Cr valuation. IPO expected in November 2025, raising ₹2,200–2,400 Cr.
🔬 Their Truenat platform, is a battery-power
Interesting insight on their go-to-market. I thought Truenat is also a sample-to-answer solution—doesn’t require any pre-processing. Is the manual step you’re referring to in nucleic acid extraction, or something else?
0 replies
More like this
Recommendations from Medial
Niket Raj Dwivedi
•
Medial • 11m
Medial is rolling out a patch today to fix a lot of bugs and some more improvements.
Now you’ll require only 50% profile completion to access DM’s.
Some tech glitches will be fixed.
Please note- If your company or college name doesn’t showup wh
See More
13 replies11 likes
Nimesh Pinnamaneni
•
Helixworks Technologies • 1m
Why qPCR & Phenotypic Testing Must Be Displaced? – Part III
This is the third part of a deep dive into why qPCR & phenotypic testing need to be replaced. In Part I, I covered the limitations of current diagnostics & why incremental improvements aren
See More
0 replies2 likes
The next billionaire
Unfiltered and real ... • 20d
Your timeline is filled with Ghibli selfies made with ChatGPT 4o.
What you're NOT seeing is how to use 4o tech to build startups that generate INSANE value.
Scroll these 20 startup ideas from $10K to $1M monthly revenue that someone should steal:
